Cited by 145Alzheimer's disease research and treatmentsNeurological Disorders and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Geniposide, a Novel Agonist for GLP-1 Receptor, Prevents PC12 Cells from Oxidative Damage via MAP Kinase Pathway

Liu, Jianhui, Yin, Fei, Zheng, Xuxu, Jing, Jiajia, Hu, Yinhe·2007·Neurochemistry International

Abstract

Alzheimer's disease (AD) is the most common form of dementia. Glucagon-like peptide-1 (GLP-1) gives a new genre in therapeutic targets for intervention in AD with its neurotrophic and neuroprotective functions. In previous work, we identified that geniposide is a novel agonist for GLP-1 receptor, which shows neurotrophic characteristics to induce the neuronal differentiation of PC12 cells. The aim of this study is to determine whether geniposide prevents neurons from oxidative damage, and to explore its signaling pathways. The results demonstrated that geniposide increased the expression of anti-apoptotic proteins, including Bcl-2 and heme oxygenase-1 (HO-1), to antagonize the oxidative damage in PC12 cells induced by hydrogen peroxide. LY294002 (a PI3K inhibitor) inhibited the effect of geniposide increasing of Bcl-2 level by activation of MAPK, MEK and c-Raf phosphorylation in hydrogen peroxide treated PC12 cells. U0126 (a selective inhibitor of MEK) also attenuated the enhancement of geniposide on Bcl-2 level by inhibiting the phosphorylation of p90RSK in the hydrogen peroxide treated PC12 cells. All these data demonstrate that geniposide, an agonist for GLP-1 receptor, regulates expression of anti-oxidative proteins including HO-1 and Bcl-2 by activating the transcriptor of p90RSK via MAPK signaling pathway in PC12 cells.

Integrity signals

Registry

Crossref · 10.1016/j.neuint.2007.04.021

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Geniposide protects PC12 and SH-SY5Y cells from oxidative damage and apoptosis by modulating MAPK signaling, caspases, and increasing SOD and GPx.

    “geniposide has been demonstrated to protect PC12 and SH-SY5Y cells from oxidative damage and apoptotic processes, by modulating the MAPK signaling pathways and caspases expression and by increasing the levels of SOD and GPx (Liu et al., 2006; Liu et al., 2007; Yin et al., 2010a; Yin et al., 2010b; Sun et al., 2013)”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Liu, J., Yin, F., Zheng, X., Jing, J., & Hu, Y.
Affiliations
  • Chongqing Technology and Business University (CN)
  • East China Normal University (CN)
Corresponding author
Liu, Jianhui
Venue
Neurochemistry International
Publisher
Elsevier BV
Published
2007-11
Volume
51
Issue
6-7
Pages
361-369
ISSN
0197-0186 (ISSN-L)
OpenAlex
W2069612190
Cited by
145
References
28
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 6 · 2019: 16 · 2018: 10 · 2017: 12 · 2016: 12 · 2015: 9 · 2014: 10 · 2013: 8 · 2012: 10
FWCI
3.10
Type
journal article
Language
en
Open access
closed
Locations
  • Neurochemistry International (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China
  • Natural Science Foundation of Chongqing
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
geniposide, GLP-1 receptor agonists, Alzheimer's disease, oxidative stress, PC12 cells, MAPK signaling, p90RSK, Bcl-2, heme oxygenase-1, phosphatidylinositol 3-kinase, MEK, hydrogen peroxide, neuroprotection, neuronal differentiation
MeSH terms
Glucagon-Like Peptide-1 Receptor, Alzheimer Disease, Animals, Brain, Enzyme Inhibitors, Hydrogen Peroxide, Neurons, Phosphorylation, Pyrans, PC12 Cells, Receptors, Glucagon, Oxidative Stress, Neuroprotective Agents, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-raf, MAP Kinase Kinase Kinases, MAP Kinase Signaling System, Ribosomal Protein S6 Kinases, 90-kDa, Iridoids, Apoptosis Regulatory Proteins, Rats, Heme Oxygenase-1, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review